Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 3/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17239827 | 0.91 | SQOR (0.50) | CHEK1KDM1AARKITCYP1A1 | |
| SCHEMBL1436484 | 0.81 | FYN (0.56) | KDM1AARACLYFYN | |
| SCHEMBL14499523 | 0.80 | KDM1A (0.45) | CHEK1KDM1AARKITCYP1A1 | |
| SCHEMBL20282446 | 0.79 | ABL1 (0.53) | KDM1ACYP1A1CYP1B1MAPKAPK2 | |
| SCHEMBL28363455 | 0.79 | CYP1A1 (0.53) | KDM1ACYP1A1CYP1B1MAPKAPK2 | |
| SCHEMBL24476966 | 0.79 | KDM1A (0.53) | KDM1AARKITFYN | |
| SCHEMBL27440272 | 0.79 | CYP1A1 (0.47) | CHEK1KDM1AKITCYP1A1CYP1B1 | |
| SCHEMBL15577622 | 0.79 | CHEK1 (0.48) | CHEK1KDM1AKITCYP1A1CYP1B1 | |
| SCHEMBL7283631 | 0.78 | KDM1A (0.46) | CHEK1KDM1AARKITCYP1A1 | |
| SCHEMBL30870706 | 0.78 | KIT (0.46) | CHEK1KDM1AARKITCYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695135-B2 | Therapeutic catechols | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695135-B2 | Therapeutic catechols | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150322022-A1 | THERAPEUTIC CATECHOLS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322022-A1 | THERAPEUTIC CATECHOLS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322022-A1 | THERAPEUTIC CATECHOLS | COMT, SARS1, C5AR1 | CHEK1 2236/4885KDM1A 485/4885AR 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.